Loading clinical trials...

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE1/PHASE2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity

A Phase I/IIa, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASC30 Injection, for Subcutaneous Use in Participants With Obesity

NCT06679959•Ascletis Pharma (China) Co., Limited

View on ClinicalTrials.gov

Summary

This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASC30 injection

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Have provided informed consent before initiation of any study-specific procedures.
•2. Male or female participants, non-smokers, between 18 and 65 years of age (both inclusive).
•3. No clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, and other screening procedures.

Exclusion Criteria

•1. Have evidence of any clinically significant active or chronic disease.
•2. Have any prior diagnosis of diabetes mellitus (T1DM or T2DM), or rare forms of diabetes mellitus.
•3. Have an autoimmune disease, is immunosuppressed or is in any way immunocompromised.
•4. Have a history of acute or chronic pancreatitis.
•5. Participants with a known clinically significant gastric emptying abnormality.
•6. Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy.
•7. Have a history of any other condition (such as known drug or alcohol abuse, diagnosed eating disorder, or other psychiatric disorder) that, in the opinion of the Investigator, may preclude the participant from following and completing the protocol.

Locations (1)

Ascletis clinical site

San Antonio, Texas, United States

Key Dates

Start Date

September 16, 2024

Primary Completion Date

April 1, 2026

Completion Date

April 1, 2026

Last Updated

December 15, 2025

Enrollment

115

ESTIMATED participants

Conditions

Chronic Weight Management

Interventions

ASC30 Injection, for subcutaneous use or placebo

DRUG

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT06703021

ObesityOverweight+1 more

View study

COMPLETEDPHASE1

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide

NCT06972992

Chronic Weight Management

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 15, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions